Try our Advanced Search for more refined results

Expert Analysis

Lessons From Luxembourg V. Genzyme

Law360, New York (June 25, 2014, 9:05 PM EDT) -- As many practitioners know, securities fraud litigation can implicate thorny questions about whether and when public companies must disclose information that could potentially damage the company's stock value. Securities law strives to achieve "truth in securities"[1] by requiring companies to apprise investors, in good faith, of all accurate information that is "material" to the investor's evaluation of the stock's price. But as a recent First Circuit decision shows, oftentimes courts have to make close calls about whether a company stands on the right or wrong side of the law....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections

Law Firms

Companies

Government Agencies

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!